Studies on the epidemiology of oligodendroglioma diagnoses and testing for O-6-Methylguanine-DNA Methyltransferase (MGMT) promoter methylation in glioblastoma (GBM) patients may provide further insights into disparities in molecular testing rates. The gene discussed is MGMT; the disease is glioblastoma.